Nuvalent Inc. was acquired by GSK in July 2026. NUVL no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to GSK, and their dates may not have been updated since.
Clinical trial readout dates for Nuvalent Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2027.